Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1793 results
April 2022
-
StatementNovartis provides more than USD 25 million in medical aid to patients in Ukraine and bordering countries
-
Media ReleaseSandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolioBrimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1 Ocular hypertension affects over 5% of all adults2; the…
-
Media ReleaseNovartis announces early clinical data for unique KRASG12C inhibitor at American Association for Cancer Research annual meetingJDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor, shows 57% confirmed ORR at recommended dose of 200 mg twice daily in Phase Ib study in patients with…
-
Tackling the health toll of climate change
-
Media ReleaseNovartis announces anti-PD-1 tislelizumab accepted by EMA for regulatory review in esophageal and lung cancersEuropean Medicines Agency validated MAAs for tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indicationsSubmissions based on data from Phase III RATIONALE…
-
Media ReleaseSandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025Both parties strengthening…
-
Media ReleaseFDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is…
-
Media ReleaseNovartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosisPhase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrated the efficacy and safety of continuous Kesimpta® (ofatumumab) treatment and in those switched from teriflunomide, with…
-
Media ReleaseNovartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facilityClearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (…
-
Key ReleaseNovartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivityAd hoc announcement pursuant to Art. 53 LRNew simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of…
-
Key ReleaseNovartis gibt neue Organisationsstruktur bekannt für schnelleres Wachstum, eine stärkere Pipeline und höhere ProduktivitätAd-hoc-Mitteilung gemäss Art. 53 KRDie neue, vereinfachte Struktur und Organisation werden die Strategie von Novartis als fokussiertes Arzneimittelunternehmen unterstützen und die nächste Phase…
Pagination
- ‹ Previous page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- …
- 150
- › Next page